Keros Therapeutics, Inc. (KROS) 股票分析

公司概述

Keros Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development and commercialization of novel therapeutics for patients in the United States suffering from disorders associated with dysfunctional signaling within the transforming growth factor-beta family of proteins. The company functions within the Healthcare sector, specifically focusing on the Biotechnology industry, which implies a reliance on advanced research and regulatory approval processes before generating significant commercial revenue. With a total market capitalization of $380.52M, an annual revenue of $244.06M, and an employee base of 78, the company presents a specific profile for mid-sized biotechnology entities. The market cap figure of $380.52M relative to the revenue of $244.06M indicates a valuation that reflects significant investor expectations for future product launches, given that the current revenue stream likely represents early-stage commercialization or specific licensing activities rather than full-scale blockbuster sales.

财务健康

The company reported a trailing twelve-month revenue of $244.06M and a net income of $87.01M, with an EBITDA of $72.08M. The substantial gap between the revenue of $244.06M and the net income of $87.01M reveals a highly efficient cost structure where operating expenses are exceptionally low relative to the generated top line, allowing for a net profit margin of 35.7%. Free cash flow stands at $66.24M, indicating that the company generates sufficient cash to fund operations without needing to raise external capital, thereby providing strong financial flexibility for research and development initiatives. While the gross margin is recorded at 47.9%, the operating margin is reported as -7576.6%, a metric that typically suggests specific accounting classifications or one-time adjustments in the reporting period, while the profit margin remains positive at 35.7%. In terms of leverage, the company holds $287.42M in cash against $16.88M in debt, resulting in a debt-to-equity ratio of 5.57, which suggests a highly conservative balance sheet with minimal interest-bearing obligations. The current ratio of 15.45 further underscores an extremely robust short-term liquidity position, ensuring the ability to meet short-term obligations without stress. Additionally, the return on equity is 19.9% and the return on assets is 9.2%, metrics that indicate management is utilizing shareholder capital and total assets with notable effectiveness to generate returns.

估值评估

The valuation metrics show a trailing P/E ratio of 5.45 and a forward P/E of -2.47, a difference that implies market expectations regarding the trajectory of future earnings are currently negative or that earnings estimates have been adjusted significantly downward for the upcoming period. The price-to-book ratio stands at 0.81, indicating that the company's market capitalization trades at a discount to its book value, suggesting the market may be pricing in risks related to the clinical-stage nature of the business. Alternative valuation metrics include a price-to-sales ratio of 1.56 and an EV/EBITDA of -0.34, which suggest the market is valuing the company based on revenue multiples rather than traditional earnings multiples due to the current earnings dynamics. The stock has experienced a trading range with a 52-week high of $22.55 and a 52-week low of $9.12. Assuming the current market data reflects the valuation context provided, the price metrics highlight the volatility inherent in clinical-stage biotechnology stocks where the distance between the high and low represents a significant swing in investor sentiment. The beta value is 0.99, meaning the stock's price volatility relative to the broader market is roughly in line with the overall market index, showing no significant amplification or dampening of market movements.

Growth & Income

The revenue growth year-over-year is recorded as -87.3%, while the earnings growth year-over-year is listed as N/A. The negative revenue growth figure indicates a contraction in sales or a specific shift in the commercialization timeline, whereas the lack of reported earnings growth data prevents a direct comparison of earnings velocity against revenue velocity at this specific reporting interval. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, which implies that retained earnings are being reinvested directly into growth initiatives such as clinical trials and pipeline expansion. This reinvestment strategy is typical for clinical-stage biopharmaceutical companies that prioritize capital allocation toward research and development over shareholder returns during the early phases of product commercialization. The overall growth and income profile is characterized by significant revenue contraction in the current period, zero dividend yield, and a reliance on internal cash generation to fund future development milestones.